Skip to main content
SpringerLink
Log in

The Importance of the Comparator in Economic Evaluations

Working on the Efficiency Frontier

  • Methodological Note
  • Working on the Efficiency Frontier
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. C

References

  1. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006

    Google Scholar 

  2. Goeree R, O’Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999 Dec; 16 (6): 679–97

    Article  PubMed  CAS  Google Scholar 

  3. Van Brabandt H, Camberlin C, Neyt M, et al. Cardiac resynchronisation therapy: a health technology assessment. Brussels: KCE, 2010

    Google Scholar 

  4. Bristow MR, Saxon LA, Boehmer J, et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 May 20; 350 (21): 2140–50

    Article  PubMed  CAS  Google Scholar 

  5. Neyt M, Thiry N, Ramaekers D, et al. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy 2008; 6 (1): 67–80

    Article  PubMed  Google Scholar 

  6. Van Brabandt H, Thiry N, Neyt M, et al. The implantable cardioverter defibrillator: a health technology assessment. Brussels: KCE, 2007

    Google Scholar 

  7. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007 Nov 3; 335 (7626): 925

    Article  PubMed  Google Scholar 

  8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 Feb 23; 354 (8): 809–20

    Article  PubMed  CAS  Google Scholar 

  9. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 Jan 6; 369 (9555): 29–36

    Article  PubMed  CAS  Google Scholar 

  10. Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet 2007 Jan 6; 369 (9555): 3–5

    Article  PubMed  Google Scholar 

  11. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess 2009; 13 Suppl. 1: 1–6

    Google Scholar 

  12. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer:NICE technology appraisal guidance. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA107guidance.pdf [Accessed 2011 Sep 21]

    Google Scholar 

  13. Huybrechts M, Hulstaert F, Neyt M, et al. Trastuzumab in early stage breast cancer: a health technology assessment. Brussels: KCE, 2006

    Google Scholar 

  14. Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008 Aug; 87 (2): 146–59

    Article  PubMed  Google Scholar 

  15. Finnish Breast Cancer Group. The Synergism Or Long Duration (SOLD) study [ClinicalTrials.gov identifier NCT00593697]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00593697?term=NCT00593697&rank=1 [Accessed 2011 Sep 21]

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to prepare this article. The authors have no conflicts of interest that are directly relevant to the content of this article. The opinions expressed in this paper are those of the authors.

Author information

Authors and Affiliations

  1. Belgian Health Care Knowledge Centre (KCE), Kruidtuinlaan, 55, 1000, Brussels, Belgium

    Mattias Neyt & Hans Van Brabandt

Authors
  1. Mattias Neyt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Van Brabandt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mattias Neyt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neyt, M., Van Brabandt, H. The Importance of the Comparator in Economic Evaluations. Pharmacoeconomics 29, 913–916 (2011). https://doi.org/10.2165/11595260-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11595260-000000000-00000

Keywords

Search

Navigation